KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Tax Provisions (2016 - 2025)

Jazz Pharmaceuticals has reported Tax Provisions over the past 14 years, most recently at $5.0 million for Q4 2025.

  • Quarterly Tax Provisions rose 108.65% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$312.4 million through Dec 2025, down 241.79% year-over-year, with the annual reading at -$272.4 million for FY2025, 198.03% down from the prior year.
  • Tax Provisions was $5.0 million for Q4 2025 at Jazz Pharmaceuticals, up from -$242.4 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $228.6 million in Q2 2021 and troughed at -$242.4 million in Q3 2025.
  • The 5-year median for Tax Provisions is -$17.2 million (2025), against an average of -$21.5 million.
  • Biggest five-year swings in Tax Provisions: surged 317.19% in 2021 and later plummeted 3164.8% in 2023.
  • Tracing JAZZ's Tax Provisions over 5 years: stood at -$12.5 million in 2021, then plummeted by 701.07% to -$100.0 million in 2022, then soared by 66.91% to -$33.1 million in 2023, then plummeted by 74.93% to -$57.9 million in 2024, then skyrocketed by 108.65% to $5.0 million in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $5.0 million, -$242.4 million, and -$17.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.